- Home
- TRVI vs TNGX Comparison
TRVI vs TNGX Comparison
Compare TRVI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- TNGX
- Stock Information
- Founded
- TRVI 2011
- TNGX 2014
- Country
- TRVI United States
- TNGX United States
- Employees
- TRVI N/A
- TNGX N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- TNGX Health Care
- Exchange
- TRVI Nasdaq
- TNGX Nasdaq
- Market Cap
- TRVI 383.4M
- TNGX 317.4M
- IPO Year
- TRVI 2019
- TNGX N/A
- Fundamental
- Price
- TRVI $6.50
- TNGX $1.47
- Analyst Decision
- TRVI Strong Buy
- TNGX Strong Buy
- Analyst Count
- TRVI 8
- TNGX 7
- Target Price
- TRVI $17.56
- TNGX $12.33
- AVG Volume (30 Days)
- TRVI 4.4M
- TNGX 835.4K
- Earning Date
- TRVI 03-18-2025
- TNGX 05-07-2025
- Dividend Yield
- TRVI N/A
- TNGX N/A
- EPS Growth
- TRVI N/A
- TNGX N/A
- EPS
- TRVI N/A
- TNGX N/A
- Revenue
- TRVI N/A
- TNGX $42,069,000.00
- Revenue This Year
- TRVI N/A
- TNGX N/A
- Revenue Next Year
- TRVI N/A
- TNGX N/A
- P/E Ratio
- TRVI N/A
- TNGX N/A
- Revenue Growth
- TRVI N/A
- TNGX 15.17
- 52 Week Low
- TRVI $2.30
- TNGX $1.43
- 52 Week High
- TRVI $7.39
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- TRVI 66.37
- TNGX 28.54
- Support Level
- TRVI $6.22
- TNGX $1.48
- Resistance Level
- TRVI $6.79
- TNGX $1.66
- Average True Range (ATR)
- TRVI 0.40
- TNGX 0.16
- MACD
- TRVI -0.03
- TNGX -0.00
- Stochastic Oscillator
- TRVI 52.24
- TNGX 6.56
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.